XNAS · Healthcare · Biotechnology
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.59 | -0.33 | +44.07% | $18.7M | ✅ Beat | +0.00% | +3.98% | — |
| 2026-05-12 | Q1 2026 | -0.66 | -0.58 | +12.12% | $12.6M | ✅ Beat | -1.03% | +5.82% | +3.36% |
| 2026-03-23 |
| Q4 2025 |
| -0.74 |
| 0.81 |
| +209.46% |
| $13.7M |
| ✅ Beat |
| +3.56% |
| +4.77% |
| +9.41% |
| 2025-11-13 | Q3 2025 | -0.03 | -0.11 | -266.67% | $19.1M | ❌ Miss | — | — | — |
| 2025-08-14 | Q2 2025 | -0.08 | -0.16 | -100.00% | $8.1M | mixed | +0.00% | -4.65% | +4.82% |
| 2025-03-11 | Q4 2024 | -0.24 | -0.20 | +16.67% | $1.7M | ✅ Beat | +4.10% | -2.21% | -16.53% |
| 2024-11-07 | Q3 2024 | -0.25 | -0.22 | +12.00% | $2.3M | ✅ Beat | -4.80% | -7.95% | +3.85% |
| 2024-05-14 | Q1 2024 | -0.11 | -0.59 | -436.36% | $0 | ❌ Miss | +2.75% | +10.09% | -3.67% |
Showing last 8 quarters.